AER vs. RPRX, CCCS, SOFI, TRTN, URI, AL, MGRC, UPBD, PRG, and CTOS
Should you be buying AerCap stock or one of its competitors? The main competitors of AerCap include Royalty Pharma (RPRX), CCC Intelligent Solutions (CCCS), SoFi Technologies (SOFI), Triton International (TRTN), United Rentals (URI), Air Lease (AL), McGrath RentCorp (MGRC), Upbound Group (UPBD), PROG (PRG), and Custom Truck One Source (CTOS).
AerCap (NYSE:AER) and Royalty Pharma (NASDAQ:RPRX) are both large-cap finance companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, media sentiment, analyst recommendations, institutional ownership, risk, dividends, earnings, profitability and community ranking.
AerCap pays an annual dividend of $1.00 per share and has a dividend yield of 1.1%. Royalty Pharma pays an annual dividend of $0.84 per share and has a dividend yield of 3.1%. AerCap pays out 6.5% of its earnings in the form of a dividend. Royalty Pharma pays out 62.7% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years.
AerCap has a beta of 1.84, suggesting that its share price is 84% more volatile than the S&P 500. Comparatively, Royalty Pharma has a beta of 0.47, suggesting that its share price is 53% less volatile than the S&P 500.
AerCap has higher revenue and earnings than Royalty Pharma. AerCap is trading at a lower price-to-earnings ratio than Royalty Pharma, indicating that it is currently the more affordable of the two stocks.
AerCap has a net margin of 42.78% compared to Royalty Pharma's net margin of 35.70%. Royalty Pharma's return on equity of 22.94% beat AerCap's return on equity.
96.4% of AerCap shares are held by institutional investors. Comparatively, 54.4% of Royalty Pharma shares are held by institutional investors. 0.5% of AerCap shares are held by insiders. Comparatively, 18.9% of Royalty Pharma shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
AerCap received 232 more outperform votes than Royalty Pharma when rated by MarketBeat users. Likewise, 74.36% of users gave AerCap an outperform vote while only 67.96% of users gave Royalty Pharma an outperform vote.
AerCap currently has a consensus target price of $96.88, suggesting a potential upside of 4.49%. Royalty Pharma has a consensus target price of $46.75, suggesting a potential upside of 70.56%. Given Royalty Pharma's higher probable upside, analysts clearly believe Royalty Pharma is more favorable than AerCap.
In the previous week, Royalty Pharma had 3 more articles in the media than AerCap. MarketBeat recorded 9 mentions for Royalty Pharma and 6 mentions for AerCap. Royalty Pharma's average media sentiment score of 1.26 beat AerCap's score of 0.66 indicating that Royalty Pharma is being referred to more favorably in the news media.
Summary
AerCap beats Royalty Pharma on 10 of the 19 factors compared between the two stocks.
Get AerCap News Delivered to You Automatically
Sign up to receive the latest news and ratings for AER and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
